Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy

Biochemical Pharmacology

Volumn 80, Issue 1, 2010, Pages 72-79

  Patwardhan, Gauri ^a   Gupta, Vineet ^a   Huang, Juowen ^a   Gu, Xin ^b   Liu, Yong Yu ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^b Louisiana State University School of Medicine Shreveport   (United States)

Author keywords

Accumulation; Cancer; Drug resistance; Efflux; Fluorescence; P glycoprotein; Paclitaxel

Indexed keywords

GLYCOPROTEIN P; PACLITAXEL;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL ASSAY; CELL MEMBRANE TRANSPORT; COLON CANCER; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN TRANSPORT; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SPECTROFLUOROMETRY; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; HUMANS; KINETICS; NEOPLASMS; P-GLYCOPROTEIN; RNA, MESSENGER; TAXOIDS;

EID: 77952255867     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.03.010     Document Type: Article

References (51)

1. Hait W.N., Yang J.M. Clinical management of recurrent breast cancer: development of multidrug resistance (MDR) and strategies to circumvent it. Semin Oncol 2005, 32:S16-S21.
2. Perez-Tomas R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 2006, 13:1859-1876.
3. Gonzalez-Angulo A.M., Morales-Vasquez F., Hortobagyi G.N. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 2007, 608:1-22.
4. Wilson T.R., Johnston P.G., Longley D.B. Anti-apoptotic mechanisms of drug resistance in cancer. Curr Cancer Drug Targets 2009, 9:307-319.
5. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5:219-234.
6. Liu Y.Y., Han T.Y., Giuliano A.E., Cabot M.C. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J 2001, 15:719-730.
7. Wu C.P., Calcagno A.M., Ambudkar S.V. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol 2008, 1:93-105.
8. Leonard G.D., Fojo T., Bates S.E. The role of ABC transporters in clinical practice. Oncologist 2003, 8:411-424.
9. Gouaze V., Liu Y.Y., Prickett C.S., Yu J.Y., Giuliano A.E., Cabot M.C. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res 2005, 65:3861-3867.
10. Gottesman M.M., Fojo T., Bates S.E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002, 2:48-58.
11. Eckford P.D., Sharom F.J. ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev 2009, 109:2989-3011.
12. Schrag D., Garewal H.S., Burstein H.J., Samson D.J., Von Hoff D.D., Somerfield M.R. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 2004, 22:3631-3638.
13. Mohan H.K., Miles K.A. Cost-effectiveness of 99mTc-sestamibi in predicting response to chemotherapy in patients with lung cancer: systematic review and meta-analysis. J Nucl Med 2009, 50:376-381.
14. Claret L., Girard P., Hoff P.M., Van Cutsem E., Zuideveld K.P., Jorga K., et al. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol 2009, 27:4103-4108.
15. Kern D.H., Weisenthal L.M. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 1990, 82:582-588.
16. Samson D.J., Seidenfeld J., Ziegler K., Aronson N. Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol 2004, 22:3618-3630.
17. Kim H.S., Kim T.J., Chung H.H., Kim J.W., Kim B.G., Park N.H., et al. In vitro extreme drug resistance assay to taxanes or platinum compounds for the prediction of clinical outcomes in epithelial ovarian cancer: a prospective cohort study. J Cancer Res Clin Oncol 2009.
18. Karam A.K., Karlan B.Y. Extreme drug resistance assay does not influence survival in women with epithelial ovarian cancer. Gynecol Oncol 2009.
19. DeVita V.T., Hellman S., Rosenberg S.A. Devita, Hellman, and Rosenberg's Cancer: Principle & Practice of Oncology. 2008 2009, Philadelphia, Lippincott Williams & Wilkins.
20. Arceci R.J. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 1993, 81:2215-2222.
21. Olesen L.H., Norgaard J.M., Pallisgaard N., Bukh A., Hokland P. Validation and clinical implication of a quantitative real-time PCR determination of MDR1 gene expression: comparison with semi-quantitative PCR in 101 patients with acute myeloid leukemia. Eur J Haematol 2003, 70:296-303.
22. Punyammalee B., Manoromana S., Purisa W., Chariyalertsak S., Rerkamnuaychok B. Association of mdr1 gene expression with other prognostic factors and clinical outcome in human breast cancer. J Med Assoc Thai 1997, 80(Suppl. 1):S162-S173.
23. Orina J.N., Calcagno A.M., Wu C.P., Varma S., Shih J., Lin M., et al. Evaluation of current methods used to analyze the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Mol Cancer Ther 2009, 8:2057-2066.
24. Fujimaki S., Funato T., Harigae H., Fujiwara J., Kameoka J., Meguro K., et al. Quantitative analysis of a MDR1 transcript for prediction of drug resistance in acute leukemia. Clin Chem 2002, 48:811-817.
25. Zhang J.T. Use of arrays to investigate the contribution of ATP-binding cassette transporters to drug resistance in cancer chemotherapy and prediction of chemosensitivity. Cell Res 2007, 17:311-323.
26. van der Holt B., Van den Heuvel-Eibrink M.M., Van Schaik R.H., van der Heiden I.P., Wiemer E.A., Vossebeld P.J., et al. ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients. Clin Pharmacol Ther 2006, 80:427-439.
27. Zhang J.T., Ling V. Study of membrane orientation and glycosylated extracellular loops of mouse P-glycoprotein by in vitro translation. J Biol Chem 1991, 266:18224-18232.
28. Kramer R., Weber T.K., Arceci R., Ramchurren N., Kastrinakis W.V., Steele G., et al. Inhibition of N-linked glycosylation of P-glycoprotein by tunicamycin results in a reduced multidrug resistance phenotype. Br J Cancer 1995, 71:670-675.
29. Yang J.M., Chin K.V., Hait W.N. Interaction of P-glycoprotein with protein kinase C in human multidrug resistant carcinoma cells. Cancer Res 1996, 56:3490-3494.
30. Kannan P., John C., Zoghbi S.S., Halldin C., Gottesman M.M., Innis R.B., et al. Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther 2009, 86:368-377.
31. Homolya L., Hollo M., Muller M., Mechetner E.B., Sarkadi B. A new method for a quantitative assessment of P-glycoprotein-related multidrug resistance in tumour cells. Br J Cancer 1996, 73:849-855.
32. Piwnica-Worms D., Chiu M.L., Budding M., Kronauge J.F., Kramer R.A., Croop J.M. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993, 53:977-984.
33. Fairchild C.R., Ivy S.P., Kao-Shan C.S., Whang-Peng J., Rosen N., Israel M.A., et al. Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells. Cancer Res 1987, 47:5141-5148.
34. Rogan A.M., Hamilton T.C., Young R.C., Klecker R.W., Ozols R.F. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 1984, 224:994-996.
35. Akiyama S., Fojo A., Hanover J.A., Pastan I., Gottesman M.M. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet 1985, 11:117-126.
36. Lai G.M., Chen Y.N., Mickley L.A., Fojo A.T., Bates S.E. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer 1991, 49:696-703.
37. Patwardhan G.A., Zhang Q.J., Yin D., Gupta V., Bao J., Senkal C.E., et al. A new mixed-backbone oligonucleotide against glucosylceramide synthase Sensitizes multidrug-resistant tumors to apoptosis. PLoS One 2009, 4:e6938.
38. Diaz J.F., Strobe R., Engelborghs Y., Souto A.A., Andreu J.M. Molecular recognition of taxol by microtubules. Kinetics and thermodynamics of binding of fluorescent taxol derivatives to an exposed site. J Biol Chem 2000, 275:26265-26276.
39. Rinaldi M., Cauchi C., Gridelli C. First line chemotherapy in advanced or metastatic NSCLC. Ann Oncol 2006, 17(Suppl. 5):v64-v67.
40. Marcus A.I., O'Brate A.M., Buey R.M., Zhou J., Thomas S., Khuri F.R., et al. Farnesyltransferase inhibitors reverse taxane resistance. Cancer Res 2006, 66:8838-8846.
41. Diaz J.F., Barasoain I., Andreu J.M. Fast kinetics of Taxol binding to microtubules. Effects of solution variables and microtubule-associated proteins. J Biol Chem 2003, 278:8407-8419.
42. Walle U.K., Walle T. Taxol transport by human intestinal epithelial Caco-2 cells. Drug Metab Dispos 1998, 26:343-346.
43. Sela S., Husain S.R., Pearson J.W., Longo D.L., Rahman A. Reversal of multidrug resistance in human colon cancer cells expressing the human MDR1 gene by liposomes in combination with monoclonal antibody or verapamil. J Natl Cancer Inst 1995, 87:123-128.
44. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003, 100:3983-3988.
45. Gupta V., Patwardhan G.A., Zhang Q.J., Cabot M.C., Jazwinski S.M., Liu Y.Y. Direct quantitative determination of ceramide glycosylation in vivo: a new approach to evaluate cellular enzyme activity of glucosylceramide synthase (GlcT-1). J Lipid Res 2010, 51:866-874.
46. Liu Y.Y., Yu J.Y., Yin D., Patwardhan G.A., Gupta V., Hirabayashi Y., et al. A role for ceramide in driving cancer cell resistance to doxorubicin. FASEB J 2008, 22:2541-2551.
47. Kessel D., Beck W.T., Kukuruga D., Schulz V. Characterization of multidrug resistance by fluorescent dyes. Cancer Res 1991, 51:4665-4670.
48. Jang S.H., Wientjes M.G., Au J.L. Determinants of paclitaxel uptake, accumulation and retention in solid tumors. Invest New Drugs 2001, 19:113-123.
49. Jang S.H., Wientjes M.G., Au J.L. Kinetics of P-glycoprotein-mediated efflux of paclitaxel. J Pharmacol Exp Ther 2001, 298:1236-1242.
50. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993, 62:385-427.
51. Rosati A., Candussio L., Crivellato E., Klugmann F.B., Giraldi T., Damiani D., et al. Bodipy-FL-verapamil: a fluorescent probe for the study of multidrug resistance proteins. Cell Oncol 2004, 26:3-11.